SpecificationsOrganism/cell line/tissue*Homo sapiens*SexFemaleSequencer or array typeAgilent SurePrint G3 Human Gene Expression v2 8 × 60K MicroarrayData formatRaw data: TAR. Normalized data: SOFT, MINiML, TXT.Experimental factorsGene expression profiling in breast cancer tissues vs. normal controlsExperimental featuresThirty-two human breast tissues of three different breast cancer subtypes (including Luminal A, Luminal B, Triple negative) and normal controls were examined with Agilent microarray technology for gene expression profiling. The breast cancer subtypes were determined by pathology report of positive or negative status of ER, PR and HER2.ConsentAll patients consented before starting the study.Sample source locationClinical and Translational Science Institute (CTSI), University of Florida, Gainesville, Florida, United States.

Direct link to deposited data {#s9015}
=============================

<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE57297>

Experimental design, materials and methods {#s0015}
==========================================

Tissue samples {#s0020}
--------------

Tissue samples were acquired from the Clinical and Translational Science Institute (CTSI) at University of Florida, covering three subtypes of breast cancer (Luminal A, Luminal B, Triple negative) [@bb0005], [@bb0010] as well as matched or unmatched normal tissue samples. All the human tissue samples were stored at − 80 °C before use.

RNA preparation {#s0025}
---------------

Total RNA was isolated and purified from frozen tissue samples using RNeasy Lipid Tissue Mini Kit and RNase-Free DNase Set (Qiagen, Chatsworth, CA) according to manufacturer\'s protocols. The quality of total RNA was strictly controlled by several parameters. The RNA extracts were first analyzed by Nanodrop 2000 (Thermo Fisher Scientific, Waltham, MA) and gel electrophoresis. RNA quality was determined by the A260/A280 ratio (close to 2), A260/A230 (close to 2), and the presence of two distinct ribosomal bands on gel electrophoresis. Qualified RNAs were further tested using Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA), and samples with 28S/18S RNA ratio \> 1 were selected for gene expression profiling [@bb0015]. Thirty-two samples were finally tested, among which two samples C501 (Luminal A) and N513 (normal) were from the same patient, others are unmatched samples.

RNA labeling and hybridization {#s0030}
------------------------------

Cyanine-3 (Cy3) labeled cRNA was prepared from 100 ng RNA using the One-Color Low Input Quick Amp labeling kit (Agilent, Valencia, CA) according to manufacturer\'s instructions, followed by RNeasy Mini Kit (Qiagen, Valencia, CA) purification. Dye incorporation and cRNA yield were checked with the NanoDrop Spectrophotometer (NanoDrop Technologies, Inc.).

RNA hybridization {#s0035}
-----------------

For hybridization, 0.6 μg of Cy3-labeled cRNA [@bb0020] (specific activity \> 8 pmol Cy3/μg cRNA) was fragmented at 60 °C for 30 min in a reaction volume of 25 μL containing 1× Agilent fragmentation buffer and 2 × Agilent blocking agent following manufacturers \' instructions. On completion of the fragmentation reaction, 25 μL of 2× Agilent hybridization buffer was added to the fragmentation mixture and hybridized to Agilent Whole Human Genome Oligo Microarrays ([GPL17077](ncbi-geo:GPL17077){#ir0030}) for 17 h at 65 °C in a rotating Agilent hybridization oven.

Microarray scanning {#s0040}
-------------------

After hybridization, microarrays were washed for 1 min at room temperature with GE Wash Buffer 1 (Agilent) and 1 min with 37 °C GE Wash buffer 2 (Agilent), then dried using Agilent stabilization and drying solution. Slides were scanned immediately after washing on the Agilent DNA Microarray Scanner (G2505C) using one color scan setting for 1 × 60k array slides (Scan Area 61 × 21 mm, Scan resolution 3 μM, Dye channel is set to Green and Green PMT is set to 100%) [@bb0025].

Data normalization and quality control {#s0045}
--------------------------------------

The raw signals were log transformed and normalized using the Percentile shift normalization method, the value was set at 75th percentile (Agilent GeneSpring 12.6 manual, 22.2.1, P584) [@bb0030]. For each probe, the median of the log summarized values from all the samples was calculated and subtracted from each of the samples to get transformed baseline. The parameter values for experimental grouping were set as Luminal A, Luminal B, Triple negative, and Normal.

Probes with normalized intensity values below 20th percentile were filtered out using the "Filter probe sets by Expression" option. This resulted in 42,875 genes, which were further filtered to exclude probes with standard deviation \< 1 in all groups, resulting in 16,822 genes.

Differential expression {#s0050}
-----------------------

Volcano plots, representing the distribution of the fold changes and p-values (obtained from moderated *t*-test [@bb0035]) of the above 16,822 genes, were shown in [Fig. 1](#f0005){ref-type="fig"} corresponding to each subgroup (Luminal A, Luminal B, and Triple negative). The moderated *t*-test is one of the statistical tests provided by the GeneSpring 12.6 software as a modification of the unpaired *t*-test (Agilent GeneSpring 12.6 manual, 22.3.7, P589).

Furthermore, 779 genes were identified with p-value ≤ 0.05 (One-Way ANOVA with asymptotic computation and Benjamin--Hochberg multiple testing corrections) and fold change ≥ 2 [@bb0040], [@bb0045] in all three breast cancer subtypes. The heat map for these 779 genes is shown in [Fig. 2](#f0010){ref-type="fig"}.

Conclusion {#s0005}
==========

Herein we described the gene regulation information for breast cancer gene profiling using Agilent SurePrint G3 Human Gene Expression Microarray technology. Our gene expression microarray data provided an important resource for exploring and identifying gene biomarkers involved in breast cancer.
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![Volcano plots showing the distribution of the gene expression fold changes in each subgroup (A) Luminal A, (B) Luminal B, and (C) Triple negative compared with normal controls. Genes with absolute fold change ≥ 2 and p-value ≤ 0.05 are indicated in red. Plots are generated using GeneSpring 12.6 with moderated *t*-test and Benjamini --Hochberg testing correction.](gr1){#f0005}

![Heat map showing different expression pattern of 779 genes out of 50,739 biological probes after one-way ANOVA test with a corrected p-value \< 0.05 and fold change ≥ 2 in all three breast cancer subtypes using GeneSpring 12.6 software. The heat map indicates up-regulation (red), down-regulation (green), and mean gene expression (black). The columns represent individual tissue samples covering three breast cancer subtypes: Luminal A (red), Luminal B (yellow), and Triple negative (purple) as well as normal samples (blue). The rows represent individual genes.](gr2){#f0010}
